Startup · $56m raised · AI
Sydney, NSW
Every investor coverage indicates participated in a round Lumonus raised.
| Investor | Rounds | Invested |
|---|---|---|
| Aviron Investment Management | Series B · Series B · Series B | - |
| Brandon Capital | Series B · Series B | - |
| Investible | Series B · Series B | - |
| Oncology Ventures | Series B · Series B · Series B | - |
Companies Lumonus acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Lumonus. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Investible explains its venture model and reports drawing $50m last year for its third early-stage fund and Club vehicle, with LumonusAI and Outlier Space in the portfolio.
Also Startup Daily
Brandon Capital has put roughly $60 million of National Reconstruction Fund money into ten biotech companies and warns R&D tax changes would hurt deep tech; portfolio company Myricx Bio went to Novartis.
Also australiatimes.com
Lumonus, a GenesisCare spinout chaired by Merrick Howes, is partnering with a New York cancer centre to co-develop automated radiotherapy planning tools.
A weekly roundup detailing new funding rounds for six Australian startups: Lyka, PlasmaLeap, Firmable, Veyor, Lumonus and Future Minds Network, with investors and round details.
Investible announces it backed Lumonus' A$28 million round with three co-investors, the first deal from its new early-stage fund; Lumonus builds AI software that automates cancer clinic workflows.
Roundup of eight funding deals: Synchron's Series D, plus raises by Lumonus AI, Hullbot, Nbryo, Cytophenix, Giftbee, Understanding Zoe and Zeligate, spanning medtech, robotics, agtech and AI.
Also Startup Daily·Startup Daily·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily
Sydney health-tech firm Lumonus AI has secured a $25 million Series B led by Aviron Investment Management with returning backer Oncology Ventures, to grow its US presence and develop medical-data tools.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Cut Through Venture·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·Forbes Australia·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com·Forbes Australia